HLHaeun Lee

Haeun Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haeun Lee has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study

    by Cindy X. Cai, Brian Toy, Benjamin Martin, Ruochong Fan, Erik Westlund, Diep Tran, Akihiko Nishimura, Haeun Lee, Theodore Leng, Paul Nagy, et al.


  • Comparison of Cardiovascular Events in Patients Receiving Concomitant Clopidogrel and Proton Pump Inhibitors Classified by CYP2C19 Inhibitory Potency

    by Seonji Kim, Jimyung Park, Hsin Yi Chen, Christianus Heru Setiawan, Haeun Lee, Benjamin Martin, Kyung Joo Lee, George Hripcsak, Jason C. Hsu, Paul Nagy, et al.

    BACKGROUND: Proton pump inhibitors (PPIs) may potentially reduce clopidogrel’s antiplatelet effect and increase cardiovascular risk. The degree of CYP (cytochrome P450) 2C19 inhibition varies among PPIs. Few studies have evaluated individual PPIs by CYP2C19 inhibition strength across countries. This study aimed to compare the incidence of cardiovascular events between strong CYP2C19-inhibiting potency and weak CYP2C19-inhibiting potency (weak or non-CYP2C19–inhibiting PPIs) in patients receiving clopidogrel. METHODS: We conducted an international observational cohort study using 14 databases from the United States, South Korea, and Taiwan. We included patients aged ≥18 years who received clopidogrel with PPIs from 1985 to 2023. PPIs were classified into strong CYP2C19-inhibiting PPIs and weak or non-CYP2C19–inhibiting PPIs based on CYP2C19 inhibition. We compared the hazard ratios and 95% CIs for major adverse cardiovascular events, including myocardial infarction, stroke, and cardiovascular mortality, using the Cox proportional hazards model after 1:1 propensity score matching. Secondary outcomes included cardiovascular mortality, myocardial infarction, stroke, and all-cause mortality. A random-effects model calculated pooled hazard ratios and 95% CIs. Only databases meeting all diagnostic criteria were included in the meta-analysis. RESULTS: Large-scale propensity score matching identified 166 005 patient pairs. During the 365-day follow-up, the risk of major adverse cardiovascular events did not differ significantly between patients receiving clopidogrel plus strong CYP2C19-inhibiting PPIs and those receiving clopidogrel plus weak or non-CYP2C19–inhibiting PPIs (17.63 per 1000 person-years versus 16.82 per 1000 person-years; calibrated hazard ratio, 1.00 [95% CI, 0.79–1.26]). No significant difference was observed in the risk of secondary outcomes (calibrated hazard ratio, cardiovascular mortality 1.10 [95% CI, 0.87–1.39], myocardial infarction 0.98 [95% CI, 0.81–1.19], stroke 1.05 [95% CI, 0.87–1.27], and all-cause mortality 1.18 [95% CI, 0.93–1.50]). CONCLUSIONS: Concomitant use of clopidogrel and strong CYP2C19-inhibiting PPIs was not associated with a higher cardiovascular risk compared with concomitant use of clopidogrel and weak or non-CYP2C19–inhibiting PPIs. This large-scale study does not support the clinical significance of potential interactions between PPIs and clopidogrel.


  • A multidimensional hierarchical framework for sources of bias in real-world healthcare evidence: a scoping review

    by Haeun Lee, Christelle Xiong, Derek Baughman, Chen Dun, Jiayi Tong, Benjamin Martin, Harold Lehmann, Paul Nagy


  • Open Access

    Hospital Length of Stay Prediction for Planned Admissions Using Observational Medical Outcomes Partnership Common Data Model: Retrospective Study

    by Haeun Lee, Seok Kim, Hui-Woun Moon, Ho-Young Lee, Kwangsoo Kim, Se Young Jung, Sooyoung Yoo

    Background: Accurate hospital length of stay (LoS) prediction enables efficient resource management. Conventional LoS prediction models with limited covariates and nonstandardized data have limited reproducibility when applied to the general population. Objective: In this study, we developed and validated a machine learning (ML)–based LoS prediction model for planned admissions using the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM). Methods: Retrospective patient-level prediction models used electronic health record (EHR) data converted to the OMOP CDM (version 5.3) from Seoul National University Bundang Hospital (SNUBH) in South Korea. The study included 137,437 hospital admission episodes between January 2016 and December 2020. Covariates from the patient, condition occurrence, medication, observation, measurement, procedure, and visit occurrence tables were included in the analysis. To perform feature selection, we applied Lasso regularization in the logistic regression. The primary outcome was an LoS of 7 days or longer, while the secondary outcome was an LoS of 3 days or longer. The prediction models were developed using 6 ML algorithms, with the training and test set split in a 7:3 ratio. The performance of each model was evaluated based on the area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPRC). Shapley Additive Explanations (SHAP) analysis measured feature importance, while calibration plots assessed the reliability of the prediction models. External validation of the developed models occurred at an independent institution, the Seoul National University Hospital. Results: The final sample included 129,938 patient entry events in the planned admissions. The Extreme Gradient Boosting (XGB) model achieved the best performance in binary classification for predicting an LoS of 7 days or longer, with an AUROC of 0.891 (95% CI 0.887-0.894) and an AUPRC of 0.819 (95% CI 0.813-0.826) on the internal test set. The Light Gradient Boosting (LGB) model performed the best in the multiclassification for predicting an LoS of 3 days or more, with an AUROC of 0.901 (95% CI 0.898-0.904) and an AUPRC of 0.770 (95% CI 0.762-0.779). The most important features contributing to the models were the operation performed, frequency of previous outpatient visits, patient admission department, age, and day of admission. The RF model showed robust performance in the external validation set, achieving an AUROC of 0.804 (95% CI 0.802-0.807). Conclusions: The use of the OMOP CDM in predicting hospital LoS for planned admissions demonstrates promising predictive capabilities for stays of varying durations. It underscores the advantage of standardized data in achieving reproducible results. This approach should serve as a model for enhancing operational efficiency and patient care coordination across health care settings.


  • Open Access

    Hospital Length of Stay Prediction for Planned Admissions Using Observational Medical Outcomes Partnership Common Data Model: Retrospective Study (Preprint)

    by Haeun Lee, Seok Kim, Hui-Woun Moon, Ho-Young Lee, Kwangsoo Kim, Se Young Jung, Sooyoung Yoo

    BACKGROUND Accurate hospital length of stay (LoS) prediction enables efficient resource management. Conventional LoS prediction models with limited covariates and nonstandardized data have limited reproducibility when applied to the general population. OBJECTIVE In this study, we developed and validated a machine learning (ML)–based LoS prediction model for planned admissions using the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM). METHODS Retrospective patient-level prediction models used electronic health record (EHR) data converted to the OMOP CDM (version 5.3) from Seoul National University Bundang Hospital (SNUBH) in South Korea. The study included 137,437 hospital admission episodes between January 2016 and December 2020. Covariates from the patient, condition occurrence, medication, observation, measurement, procedure, and visit occurrence tables were included in the analysis. To perform feature selection, we applied Lasso regularization in the logistic regression. The primary outcome was an LoS of 7 days or longer, while the secondary outcome was an LoS of 3 days or longer. The prediction models were developed using 6 ML algorithms, with the training and test set split in a 7:3 ratio. The performance of each model was evaluated based on the area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPRC). Shapley Additive Explanations (SHAP) analysis measured feature importance, while calibration plots assessed the reliability of the prediction models. External validation of the developed models occurred at an independent institution, the Seoul National University Hospital. RESULTS The final sample included 129,938 patient entry events in the planned admissions. The Extreme Gradient Boosting (XGB) model achieved the best performance in binary classification for predicting an LoS of 7 days or longer, with an AUROC of 0.891 (95% CI 0.887-0.894) and an AUPRC of 0.819 (95% CI 0.813-0.826) on the internal test set. The Light Gradient Boosting (LGB) model performed the best in the multiclassification for predicting an LoS of 3 days or more, with an AUROC of 0.901 (95% CI 0.898-0.904) and an AUPRC of 0.770 (95% CI 0.762-0.779). The most important features contributing to the models were the operation performed, frequency of previous outpatient visits, patient admission department, age, and day of admission. The RF model showed robust performance in the external validation set, achieving an AUROC of 0.804 (95% CI 0.802-0.807). CONCLUSIONS The use of the OMOP CDM in predicting hospital LoS for planned admissions demonstrates promising predictive capabilities for stays of varying durations. It underscores the advantage of standardized data in achieving reproducible results. This approach should serve as a model for enhancing operational efficiency and patient care coordination across health care settings.